[Experimental study on monitoring gene expression by noninvasive method in XXXX VX2 @entity96 model].

@entity96 @entity5 @entity908 @entity95 @entity7748 @entity72066
OBJECTIVE: To investigate the feasibility of monitoring therapeutic effect of adenovirus vector containing IL12-IRES- @entity72066 gene on a @entity95 VX2 @entity96 model by using phosphorous-31 magnetic resonance spectroscopy (31P @entity7748 ). METHODS: A total of 18 healthy New Zealand White @entity95 were used to generate animal models by implanting VX2 @entity5 chips into livers through laparotomy. Tumor-bearing animals were randomly divided into three groups and were injected with AdCMVIL12-IRES- @entity72066 , AdCMV-Empty and saline respectively via ear veins. 31P @entity7748 scan was performed after animals were fed with @entity908 solution for five days. Animals were euthanized thereafter and @entity5 were removed for pathological examination, immunohistochemistry (IHC) staining and protein analysis (Western blot). RESULTS: The intrahepatic and seral expressions of @entity908 kinase ( @entity72066 ) and IL-12 were detected only in AdCMVIL12-IRES- @entity72066 group. Tumor diameters pre- and post- treatment in three groups were 1.63+/-0.04 vs 1.62+/-0.03 in AdCMVIL12-IRES- @entity72066 group (P = 0.229), 1.59+/-0.05 vs 1.84+/-0.11 in AdCMV-Empty group (P = 0.003) and 1.60+/-0.02 vs 2.07+/-0.12 in saline group (P = 0.001), respectively. Pcr Changes between pre- and post- treatment among the three groups were compared (F = 6.235, P value is less than 0.05). PCr increased significantly in AdCMVIL12-IRES- @entity72066 group as compared to AdCMV-Empty (P = 0.004) and saline group (P = 0.049), whereas no change found between AdCMV-Empty and saline group (P = 0.153). CONCLUSION: 31P @entity7748 , an effective and non-invasive functional imaging method, can be used to monitor the therapeutic effect of adenovirus vector containing IL12-IRES- @entity72066 gene on @entity95 VX2 @entity96 model through detecting metabolic product of imaging reporter gene @entity72066 (pCr).
